Starpharma Holdings Ltd - Company Profile
Powered by 
All the sales intelligence you need on Starpharma Holdings Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Starpharma Holdings Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Starpharma Holdings Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Starpharma Holdings Ltd (Starpharma) specializes in advancing dendrimer technology to develop innovative therapeutics. The company focuses on serious conditions, particularly cancer, through the application of its proprietary dendrimer-based technology.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Starpharma focuses on leveraging its proprietary dendrimer technology to address complex drug delivery challenges. The company's R&D strategy is centered around its DEP platform, which enhances drug characteristics such as solubility, tumor targeting, and pharmacokinetic profiles. This platform is clinically validated, with over 350 patients treated in clinical trials, and is designed for scalability and precise manufacturing. Starpharma's R&D efforts are supported by significant investments in both internal and external resources to advance discussions with prospective partners and strengthen the commercial case for its technology. The company prioritizes areas of high unmet medical need and accelerates early asset development by focusing on novel assets in emerging therapy areas. Starpharma's strategic priorities include maximizing the value of its DEP assets, advancing its radiopharmaceuticals program, and fostering a high-performance culture. The company also emphasizes building long-term sustainability through increased revenue, strengthened intellectual property positions, and productive partnerships. As of June 2025, the company had 22 active patent families, 149 granted patents, and 47 patent applications pending. In FY2025, the company spent AUD12.1 million on its R&D activities.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer